Wedbush Maintains Outperform on IGM Biosciences, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on IGM Biosciences but lowers the price target from $25 to $22.
October 01, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst Robert Driscoll maintains an Outperform rating on IGM Biosciences but lowers the price target from $25 to $22.
The Outperform rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100